anti-Homo sapiens (Human) TP53 Monoclonal Antibody raised in Mouse

Description

Introduction and Definition

TP53 Monoclonal Antibodies are laboratory-engineered immune proteins designed to specifically target the p53 tumor suppressor protein, encoded by the TP53 gene. These antibodies are critical tools in cancer research, diagnostics, and emerging therapeutic strategies. The p53 protein regulates cell cycle arrest, apoptosis, and genomic stability, and mutations in TP53 are among the most common genetic alterations in human cancers . Monoclonal antibodies (mAbs) targeting p53 are used to detect protein expression levels, identify mutant variants, and guide therapeutic interventions .

p53 Protein Overview

Feature	Description
Size	~53 kDa
Function	Transcription factor regulating apoptosis, DNA repair, and cell cycle arrest
Mutation Impact	Missense mutations (e.g., R175H) disrupt DNA binding, leading to loss of tumor suppression and oncogenic gain-of-function
Antibody Targets	Both wild-type (WT) and mutant p53, depending on epitope specificity

Monoclonal antibodies bind to specific epitopes on p53, enabling detection via techniques like immunohistochemistry (IHC), Western blot (WB), and flow cytometry. Some antibodies, such as TP53/1739 and TP53/1799R, recognize both WT and mutant p53, while others (e.g., anti-R175H mAbs) target specific mutant forms .

Key Uses of TP53 Monoclonal Antibodies

Application	Purpose	Example Uses
Immunohistochemistry	Detect p53 nuclear accumulation in tumor tissues	Differentiating uterine serous carcinoma from endometrioid carcinoma; diagnosing intratubular germ cell neoplasia
Western Blot	Quantify p53 protein levels in cell lysates	Validating p53 expression in cancer cell lines (e.g., A431, MCF-7)
Flow Cytometry	Analyze p53 expression in circulating tumor cells	Monitoring therapeutic responses in TP53-mutated AML
Molecular Imaging	Noninvasive visualization of p53 in vivo	SPECT imaging of p53 R175H tumors using 111In-anti-p53-TAT conjugates

Targeted Therapeutic Strategies

Approach	Mechanism	Clinical Status
CD47 Inhibition	Magrolimab blocks CD47-mediated immune evasion in TP53-mutated AML	Phase 3 ENHANCE-2 trial (NCT04778397)
p53 Reactivation	Eprenetapopt (APR-246) restores WT p53 function in mutant cells	Discontinued after phase 3 failure in MDS
Mutant-Specific mAbs	DNA-delivered anti-R175H mAbs induce tumor-specific cytotoxicity	Preclinical efficacy in MC38-p53-R175H models
MDM2 Inhibitors	Reactivate WT p53 by blocking MDM2-mediated degradation	Phase 1b trials (e.g., idasanutlin + venetoclax)

p53 Antibodies in Patient Sera

p53 autoantibodies (p53-Abs) are detected in ~30% of cancer patients and correlate with TP53 mutations. While highly specific (95–96%), their sensitivity is limited (~30%), making them less reliable for early detection .

Cancer Type	Prognostic Association	References
Breast, Colon, Gastric	High-grade tumors; poor survival
TP53-Mutated AML	Shorter remission duration; lower OS

TP53-Mutated Acute Myeloid Leukemia (AML)

Prevalence: 5–10% of de novo AML cases; often co-occurs with complex karyotypes .
Treatment Challenges: Poor response to standard therapies (e.g., 20–40% CR with azacitidine) .
Emerging Therapies:
- Venetoclax + Hypomethylating Agents (HMAs): CR/CRi rates of 33–47%, but short median OS (~7–12 months) .
- Magrolimab + Azacitidine: Phase 3 trial evaluating immune-mediated phagocytosis .

Challenges and Future Directions

Cross-Reactivity: Many antibodies bind WT and mutant p53, limiting specificity .
Sensitivity: p53-Abs in sera lack diagnostic utility due to low prevalence in early-stage cancers .
Targeted Imaging: Radiolabeled anti-p53 mAbs (e.g., 111In-H10-TAT) show promise for noninvasive tumor monitoring .
Bispecific Antibodies: Combinations (e.g., anti-R175H + anti-PD-1) enhance T-cell-mediated killing in preclinical models .

Product Specs

Form

Purified mouse monoclonal antibody in a buffer containing 0.1M Tris-Glycine (pH 7.4, 150 mM NaCl), supplemented with 0.2% sodium azide and 50% glycerol.

Lead Time

Typically, we can ship the product within 1-3 business days after receiving your order. Delivery times may vary depending on the shipping method and destination. For specific delivery estimates, please consult your local distributor.

Synonyms

cellular tumor antigen p53 antigen NY-CO-13 phosphoprotein p53 p53 tumor suppressor transformation-related protein 53

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

TP53 Monoclonal Antibody